Vericel Profile

USD 1.00  9.90%

Purchase by Alan Rubino of 685 shares of Vericel

Vericel Corporation insider trading alert for perchase of common stock by Alan Rubino, the corporate stakeholder, on March 16, 2018. This event was filed by Vericel Corp with SEC on 2018-03-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Vericel Summary

Vericel Corporation (VCEL) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 205 people. Vericel Corporation was previously listed under the symbol ASTM. Vericel is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 406.16 M. Vericel Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 36.1 M outstanding shares of which 1.28 M shares are at this time shorted by private and institutional investors with about 2.4 trading days to cover. Vericel Corporati currently holds about 26.86 M in cash with (13.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74.
Check Vericel Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Exposer

PriceHorizonTargetAbove OddsBelow Odds
 11.10 30 days 11.10  about 31.54% about 68.36%
Based on normal probability distribution, the odds of Vericel to move above current price in 30 days from now is about 31.54%.

Top Holders

Selected Vericel Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Vericel Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 41% 
Equity ratings for Vericel Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts. Vericel operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 205 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameVericel Corporation
CEODominick ColangeloView All
Thematic ClassificationPharmaceutical ProductsView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
Business Address64 Sidney Street
ExchangeNasdaq Capital Markets
Prior SymbolASTM
IndustryPharmaceutical Products
Contact Number617 588 5555
Related EntityASTM
CurrencyUSD - US Dollar

Current Sentiment - VCEL

Vericel Investor Sentiment
Most of Macroaxis users are at this time bullish on Vericel Corporation. What is your outlook on investing in Vericel Corporation? Are you bullish or bearish?
98% Bullish
2% Bearish
Skip  Hide


Vericel Analyst Recommendations
Target PriceAdvice# of Analysts
Vericel Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Vericel Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Vericel Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.22March 13, 2017
Vericel Corporation normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Vericel Corporate Directors
Alan Rubino Independent Director
Heidi Hagen Director, MBA
Steven Gilman Director